Full-Time

Quality Manager

Confirmed live in the last 24 hours

Amgen

Amgen

10,001+ employees

Develops biologic therapies for serious illnesses

No salary listed

Senior

Mumbai, Maharashtra, India

Category
Public Health
Biology & Biotech
Required Skills
Risk Management
Requirements
  • Pharmacist Registration in India.
  • Hold a valid practicing certificate as Pharmacist in India.
  • In-depth knowledge and experience of Good Manufacturing Practice (GMP) & Good Distribution Practice (GDP).
  • Experience with Quality Management Systems including but not limited to change control, deviation, validation, complaints, disposition and audits/inspections.
  • Experience with Commercial Quality Operations and third-party management.
Responsibilities
  • Implement Amgen Quality Management System
  • Identify Continuous Improvement opportunity for Quality Management System
  • Develop Quality Procedures align with Amgen Quality Management System, cGMP requirements, GDP requirements and local regulations
  • Oversight operations of local distributors and stockist to ensure local distributors operations are in compliance with cGMP requirements, GDP requirements, Amgen Quality Management System and Local regulations
  • Act as Quality-related interface with internal and external customers (i.e. : Change control, Non Conformance, Product Complaint, Product Recall, Audit/ Inspection)
  • Support local testing
  • Support BD project and product launches
  • Liaise with internal and external partners to manage day to day operations associated with distribution operations
  • Monitor and ensure on time completion of NC, CAPA, Audit observation, Product complaint and other quality events
  • Develop and Maintain the Quality Agreements with local distributors and partners
  • Develop reports and provide the necessary communications throughout the organizations
  • Develop or review or approve GMP and GDP documents Provide training to distributors and stockiest including distributors/stockist on-boarding training
  • Actively participate on GMP intelligence to review local regulations, standards and guidance related to Good Manufacturing Practice (GMP), Good Distribution Practice (GDP), product testing and Pharmacopoeia requirements in India.
  • Collaborate with Risk Management and Product Security on handling of counterfeit, product tempering, product theft and product diversion
  • Interact with local regulators as needed.
  • Keep the Senior Manager International Quality – JAPAC informed of the progress of projects and goals and advise on the potential areas of risk/ concern and new developments that may impact the company
  • Support Named Patient Program
  • Supplier Management: Perform quality oversight and audit of key suppliers to Amgen and its subsidiary companies. These suppliers can include API and starting material manufacturers as well as raw materials, devices and finished products suppliers, contract facilities, local laboratories, importers, distributors, logistics service providers, warehouse, etc.
  • Apply advanced knowledge of Indian and global market regulations to assess supply security risks.
  • Work on an active risk management tool etc. to appropriately deploy Quality Systems on oversight of Amgen suppliers; including selection and approval, due diligence assessment, intelligence monitoring, on-site visit/audit and (if needed) Person in Plant placement, etc..
  • Support in identifying, assessing and addressing supplier’s GMP/GDP risks in collaboration with Amgen sites.
  • Execute necessary tasks and projects as assigned by management in timely manner; to attain assigned goals.
  • Provide support for regulatory inspections of key facilities as needed.
Desired Qualifications
  • Experience with distribution models and/or establishment of new entity procedures a plus

Amgen develops medicines aimed at treating serious illnesses, focusing on biotechnology. The company researches, develops, and sells biologic therapies, which are derived from living organisms, to address conditions like cancer, cardiovascular diseases, and autoimmune disorders. Amgen's products work by utilizing biological processes to create effective treatments for patients. Unlike many competitors, Amgen emphasizes a strong commitment to research and development, reinvesting a large portion of its earnings to discover new therapies. The goal of Amgen is to improve patient care by providing effective therapeutic solutions and expanding its pipeline of potential new treatments.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Amgen's investment in AI aligns with trends in biotechnology innovation.
  • Institutional investments indicate strong market confidence in Amgen's growth.
  • FTC clearance of the Horizon merger may ease future regulatory hurdles.

What critics are saying

  • Competitors' AI-driven drug discovery could outpace Amgen's traditional R&D methods.
  • FTC scrutiny of mergers may complicate Amgen's future growth strategy.
  • Advancements in quantum technologies could pose a competitive threat to Amgen.

What makes Amgen unique

  • Amgen focuses on biologic therapies derived from living organisms.
  • The company has a strong pipeline of potential new therapies in development.
  • Amgen's acquisition of Horizon Therapeutics enhances its rare disease portfolio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

MarketBeat
Jan 28th, 2024
Factory Mutual Insurance Co. Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Factory Mutual Insurance Co. purchased a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 53,500 shares of the medical research company's stock, valued at approxim

The Quantum Insider
Jan 16th, 2024
Honeywell Announces the Closing of $300 Million Equity Investment Round for Quantinuum at $5 Billion Pre-Money Valuation

JPMorgan Chase has one of the world's most highly regarded specialist teams working on quantum technologies within the financial services industry and has been working with Quantinuum and its predecessor companies since 2020.

ETF Daily News
Dec 17th, 2023
Northwest Quadrant Wealth Management LLC Invests $237,000 in Amgen Inc. (NASDAQ:AMGN)

Northwest Quadrant Wealth Management LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 883 shares of the medical research company’s stock, valued at approximately $237,000. A number of other institutional investors […]

Horizon Therapeutics
Sep 21st, 2023
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc | Horizon Therapeutics plc

The Investor Relations website contains information about Horizon Therapeutics plc's business for stockholders, potential investors, and financial analysts.

BioSpace
Sep 19th, 2023
Amgen-Horizon Merger Clearance a Setback to FTC’s Antitrust Enforcement Plans

The consent agreement struck between the FTC and Amgen and Horizon Therapeutics could have significant implications for ongoing and future M&A challenges, experts told BioSpace.